Noseworthy will join the company’s board of directors and lead its Caire Collaborative, a consortium of health systems that act as investors, partners and early adopters of Caire’s in-person and virtual care model.
“The pandemic opened the door to a hybrid healthcare model,” Noseworthy said in a statement. “I want to see health systems at the center of that progress, identifying the most critical healthcare issues that can be addressed by innovation, artificial intelligence and digital tools. We can and should take advantage of new technology to address the gaps and disparities in care that we weren’t able to manage before. I’m excited to use my knowledge and industry experience to help create the future of healthcare.
Loyal, a digital health platform aimed at helping health systems and hospitals connect with patients, announced Matt Gove joined its team as senior advisor.
Gove previously held the position of chief marketing officer for New York-based Summit Health, a multispecialty medical practice and parent company of urgent care provider CityMD. Walgreens-backed VillageMD purchased Summit Health in November.
He also served as chief consumer officer at Georgia-based health system Piedmont Healthcare.
Gove will work directly with Loyal’s CEO, Chad Mallory, and provide strategic counseling as the company looks to expand its platform.
“It has been a thrill to see healthcare companies finally embrace their customers and offer digital tools that meet patients where they are. The next step for those companies is to find a solution that not only makes it easier for patients but delivers a consolidated platform that actually improves operations as well,” Gove said in a statement. “Loyal is the only platform that can do that, and I’m incredibly excited to be joining at this point in its growth.”
AI-enabled pathology company PathAI announced Matt Grow is joining its team as president of biopharma and chief business officer.
Grow will work to expand PathAI’s biopharma commercial organization, focusing on the company’s algorithm product suite and clinical trial service offerings for biopharma partners.
He previously served as senior vice president and global head of biopharma business development at pharmaceutical contract research organization PPD and Thermo Fisher Scientific.
“I have been supporting biopharma in this industry for over twenty years, and I am energized by the PathAI end-to-end portfolio and how the technology is advancing drug development. I am thrilled to be joining such a strong team,” Grow said in a statement. “As the portfolio continues to evolve, PathAI is strengthening its position to address the precise needs of each customer throughout the drug development spectrum. My goal is to ensure that we do this most effectively.”